Quantcast

Latest Amgen Inc. Stories

2010-10-25 15:12:00

THOUSAND OAKS, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) reported revenue unchanged for the third quarter of 2010 at $3,816 million versus $3,812 million for the third quarter of 2009. Adjusted net income decreased 14 percent to $1,313 million for the third quarter of 2010 compared to $1,518 million for the third quarter of 2009. The decrease in adjusted net income was driven by unusually low research and development (R&D) costs and favorable tax settlements in...

2010-09-03 09:30:00

VANCOUVER, Canada, Sept. 3 /PRNewswire-Asia/ -- Insiderslab.com issues new research reports that highlight large insider trades found in for Atmel, Baker Hughes, Amgen, First Solar, Human Genome Sciences, & Aruba. Read our research reports with Interactive Insider Trading Charts and Insider Trade Statistics below. Insiders refer to company Top Executive Officers (CEOs, CFOs, COOs) and Directors who are involved in making critical corporate decisions. (Read full report by...

2010-08-30 09:00:00

VANCOUVER, Canada, Aug. 30 /PRNewswire-Asia/ -- Insiderslab.com issues new research reports that highlight large insider trades found in for Netezza, Tiffany, Mattel, Amgen, Aruba Networks, & Western Digital. Read our research reports with Interactive Insider Trading Charts and Insider Trade Statistics below. Insiders refer to company Top Executive Officers (CEOs, CFOs, COOs) and Directors who are involved in making critical corporate decisions. (Read full report by...

2010-08-27 08:31:00

CHICAGO, Aug. 27 /PRNewswire/ -- Seven Summits Research issues critical PriceWatch Alerts for V, AMGN, CL, ISRG, and CTAS. To see what our analysts have discovered about these stocks read the Seven Summits Strategic Investments' PriceWatch Alerts at http://www.iotogo.com/s/082710B (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alerts cover the following stocks: Visa, Inc. (NYSE: V), Amgen Inc. (Nasdaq: AMGN), Colgate-Palmolive Co....

2010-08-24 07:00:00

NEW YORK, Aug. 24 /PRNewswire-FirstCall/ -- Regenicin, Inc. (OTC Bulletin Board: WDSTD), a clinical-stage biotechnology company, announced today that Dr. Joseph Rubinfeld, one of the four original founders of Amgen, Inc., has agreed to join the company's board of directors. Dr. Rubinfeld will be instrumental to assisting the company's commercialization efforts of PermaDerm(TM), Regenicin's proprietary autologous cultured skin substitute intended to restore the qualities of healthy human...

2010-07-29 15:05:00

THOUSAND OAKS, Calif., July 29 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.38 for the second quarter of 2010, an increase of 7 percent compared to $1.29 for the second quarter of 2009. Adjusted net income increased 1 percent to $1,326 million for the second quarter of 2010 compared to $1,311 million for the second quarter of 2009. Total revenue increased 2 percent for the second quarter of 2010 to $3,804 million versus $3,713 million...

2010-06-01 17:10:00

THOUSAND OAKS, Calif., June 1 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia(TM) (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK...

2010-05-28 03:34:00

THOUSAND OAKS, Calif., May 28 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the European Commission (EC) has granted marketing authorization for Prolia® (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. Prolia has been approved in all 27 European Union member states...

2010-05-14 15:03:00

THOUSAND OAKS, Calif., May 14 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denosumab, a subcutaneous RANK Ligand inhibitor. The BLA submission summarizes clinical experience from nearly 6,900 patients across 18 clinical studies, including approximately 5,700 patients with advanced cancer in the three, pivotal, Phase 3, head-to-head trials versus...

2010-04-21 15:06:00

THOUSAND OAKS, Calif., April 21 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.30 for the first quarter of 2010, an increase of 20 percent compared to $1.08 for the first quarter of 2009. Adjusted net income increased 14 percent to $1,282 million for the first quarter of 2010 compared to $1,120 million for the first quarter of 2009. Total revenue increased 9 percent for the first quarter of 2010 to $3,592 million versus $3,308 million...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related